New drugs, strategies and research designs for advanced non-small cell lung cancer

Hot topics
Chairs: O. Burghuber (Vienna, Austria), G. Hardavella (London, United Kingdom)
Aims: This joint hot topic session with the EORTC offers a comprehensive overview of the latest developments in the treatment of advanced lung cancer. Current treatment strategies will be described. This will help attendees to integrate the newest clinical trial knowledge into routine lung cancer care. A perspective on new lung cancer study designs will also be provided.

Modern profiling of advanced lung cancer at the primary diagnosis and during therapy S. Stephan-Falkenau (Berlin, Germany)
Immunotherapy: when, who and which drug? J. Cadranel (Paris Cedex 20, France)
Targeting targeted therapies: more choices and the best sequences J. Bar (Tel-Aviv, Israel)
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials J. Menis (Padova, Italy)